BiomeBank is a clinical stage biotechnology company developing microbial therapies to treat unmet medical need globally, with an immediate focus on the APAC region. We currently manufacture a microbial therapy to treat Clostridoides difficile, a potentially life threatening infection, and are positioning the drug product for multiple indications.Furthermore, we are actively developing second generation therapies in multiple diseases, including Ulcerative Colitis and Crohn's Disease.

Biotechnology

BiomeBank

Sam Costello

Corey Whittle

Philippa C.

Sarah Haylock-Jacobs

Paul Flynn FUniSA, MAICD, FFIA

Lisa Kirkland

Johnathon Matthews

Garrett Heiman

Chelsea Bickley

The Research and Development Team at BiomeBank focuses on advancing microbial therapies from concept to clinical application. This team is responsible for developing innovative treatments for diseases such as Ulcerative Colitis and Crohn's Disease. Their work includes process development, production, research into cultured therapies, and clinical development to ensure these therapies meet regulatory standards and address unmet medical needs effectively.

Research and Development Team

Quality Assurance and Regulatory Affairs

Research and Development Team

About

Team members

Other teams at BiomeBank

Quality Assurance and Regulatory Affairs